Neoadjuvant therapy (NT) in patients with melanoma is associated with promising survival benefits, favorable complete response (CR), and an acceptable safety profile, according to systematic review ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
Ivonescimab plus chemotherapy improved PFS by 40% compared to Tevimbra in advanced squamous NSCLC, with a median PFS of 11.14 months versus 6.9 months. The study demonstrated consistent PFS benefits ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback